You've mentioned before about our trials running in tandem
1/ How much data needs to be collected from p1a before P1b can start? Does it need all patients to be dosed (as per trial design) and data collected and/or is there a minimum amount if patient data is positive before a swift early move to P1b?
2/ (similar Q) How far into P1b before P2 can start?
3/ As per CpInvest's Q above. Are we to receive a strategic update soon? And updated timelines?
(Imo I feel like RAC is waiting on whatever is causing the blackout period to end hence the lag, but I don't know. Also a concern is Pete's use of the word "rectify" at the presso as if something's not right. )
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)